<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39558037</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Failure mode and effects analysis-based strategies for controlling multidrug-resistant organism infections in cancer patients.</ArticleTitle><Pagination><StartPage>28564</StartPage><MedlinePgn>28564</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-80282-9</ELocationID><Abstract><AbstractText>In the context of advancing medical procedures, postoperative infections in cancer patients, particularly those involving multidrug-resistant organisms, have become a significant clinical concern. This study aims to comprehensively and systematically evaluate the effectiveness of infection prevention and control for multidrug-resistant organisms (MDROs) in postoperative cancer patients using Failure Mode and Effects Analysis (FMEA). This study was conducted in a tertiary A-level cancer specialty hospital in China, employing Failure Mode and Effects Analysis (FMEA) to assess the risks of hospital infections. Intervention measures were implemented for high-risk and medium-high-risk factors. Through the hospital's infection information system, data on patients who underwent surgical treatment from 2017 to 2022 were extracted. Data from 2017 to 2019 served as the control group, and data from 2020 to 2022 as the intervention group, to compare the changes in hospital infection incidence and MDRO infection incidence before and after the intervention. Categorical data were described in terms of frequency and percentage. The chi-square test was utilized for statistical inference to assess the differences in infection rates before and after the intervention. Prior to the intervention (2017-2019), the incidence rate of hospital infections was 1.66%, which decreased to 1.22% after the intervention (2020-2022), showing a statistically significant difference (χ<sup>2</sup> = 48.83, P &lt; 0.001). The incidence rate of MDRO infections also decreased from 1.808‰ before the intervention to 1.136‰ after the intervention, with a statistically significant difference (χ<sup>2</sup> = 11.417, P = 0.001). This study confirms the effectiveness of the FMEA method in preventing and controlling MDRO infections in postoperative cancer patients. It highlights the practicality and value of widespread adoption of this method, particularly in the context of the COVID-19 pandemic.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chunlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Qingqing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Anran</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jiayang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pu</LastName><ForeName>Ruiying</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital, Chengdu, China. huangqin1@scszlyy.org.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SCGK201815</GrantID><Agency>Sichuan Preventive Medicine Association</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="Y">Cross Infection</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024901" MajorTopicYN="Y">Drug Resistance, Multiple, Bacterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017053" MajorTopicYN="N">Infection Control</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Failure mode and effects analysis</Keyword><Keyword MajorTopicYN="N">Infection control</Keyword><Keyword MajorTopicYN="N">Multidrug resistance</Keyword><Keyword MajorTopicYN="N">Neoplasms</Keyword><Keyword MajorTopicYN="N">Postoperative infections</Keyword></KeywordList><CoiStatement><b>Declarations</b> <b>Competing interests</b> The authors declare no competing interests. <b>Consent to participate declaration</b> For this study, all data were sourced from the hospital information system and anonymized to ensure patient confidentiality and privacy. Patients were informed at the time of admission that their medical records might be used for research purposes with ensured privacy, thus negating the need for separate consent for this study. This article does not contain any studies with animals conducted by any of the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39558037</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-80282-9</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-80282-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cornejo-Juarez, P. et al. Hospital-acquired infections at an oncological intensive care cancer unit: Differences between solid and hematological cancer patients. BMC Infect Dis 16, 274. https://doi.org/10.1186/s12879-016-1592-1 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1592-1</ArticleId><ArticleId IdType="pubmed">27286681</ArticleId><ArticleId IdType="pmc">4903007</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornejo-Juárez, P. et al. The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int. J. Infect. Dis. 31, 31–34. https://doi.org/10.1016/j.ijid.2014.12.022 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2014.12.022</ArticleId><ArticleId IdType="pubmed">25528484</ArticleId></ArticleIdList></Reference><Reference><Citation>Molena, D. et al. Prevalence, impact, and risk factors for hospital-acquired conditions after major surgical resection for cancer: A NSQIP analysis. J. Gastrointestinal Surg. 19(1), 142–151. https://doi.org/10.1007/s11605-014-2642-x (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-014-2642-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lago, P. et al. Use of FMEA analysis to reduce risk of errors in prescribing and administering drugs in paediatric wards: A quality improvement report. BMJ Open 2(6), e001249. https://doi.org/10.1136/bmjopen-2012-001249 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2012-001249</ArticleId><ArticleId IdType="pubmed">23253870</ArticleId><ArticleId IdType="pmc">3533113</ArticleId></ArticleIdList></Reference><Reference><Citation>Buja, A. et al. Using failure mode, effect and criticality analysis to improve safety in the cancer treatment prescription and administration process. J. Pharmaceutical Policy Practice 16(1), 9. https://doi.org/10.1186/s40545-023-00512-9 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40545-023-00512-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean, F. B., Shebl, N. A. &amp; Barber, N. Failure mode and effects analysis: Too little for too much?. BMJ Qual Saf 21(7), 607–611. https://doi.org/10.1136/bmjqs-2011-000723 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjqs-2011-000723</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam, N. M. et al. A novel approach to infectious disease control and radiotherapy risk management. Med. Phys. 50(5), 2683–2694. https://doi.org/10.1002/mp.16328 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mp.16328</ArticleId><ArticleId IdType="pubmed">36841994</ArticleId></ArticleIdList></Reference><Reference><Citation>Grau, N. et al. Risk management in the ambulatory care process in a mutual benefit association covering work-related accidents and diseases: Applying modified failure mode and effect analysis (FMEA) Methodology. J. Patient Safety 17(8), e1428. https://doi.org/10.1097/PTS.0000000000000542 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PTS.0000000000000542</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, F. et al. Validating FMEA output against incident learning data: A study in stereotactic body radiation therapy. Med Phys 42(6), 2777–2785. https://doi.org/10.1118/1.4919440 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1118/1.4919440</ArticleId><ArticleId IdType="pubmed">26127030</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, A. Y. et al. Failure modes and effects analysis (FMEA) for Gamma Knife radiosurgery. J Appl Clin Med Phys 18(6), 152–168. https://doi.org/10.1002/acm2.12205 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acm2.12205</ArticleId><ArticleId IdType="pubmed">29082599</ArticleId><ArticleId IdType="pmc">5689925</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnick, R. E. et al. Failure mode and effects analysis (FMEA) to enhance the safety and efficiency of Gamma Knife radiosurgery. J Radiosurg SBRT 7(2), 115–125 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33282465</ArticleId><ArticleId IdType="pmc">7717097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi, A. &amp; Mosallanezhad, B. Using fuzzy FMEA to increase patient safety in fundamental processes of operating room. J. Ind. Syst. Eng. 11, 146–166 (2018).</Citation></Reference><Reference><Citation>Yousefinezhadi, T. et al. A Case study on improving intensive care unit (ICU) services reliability: By using process failure mode and effects analysis (PFMEA). Glob J Health Sci 8(9), 52635. https://doi.org/10.5539/gjhs.v8n9p207 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.5539/gjhs.v8n9p207</ArticleId><ArticleId IdType="pubmed">27157162</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. et al. Use-related risk analysis for medical devices based on improved FMEA. Work 41(Suppl 1), 5860–5865. https://doi.org/10.3233/WOR-2012-0976-5860 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/WOR-2012-0976-5860</ArticleId><ArticleId IdType="pubmed">22317712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobral, J., Teixeira, D., Morais, H., et al. Methodology to assess medical processes based on a Failure Mode and Effects Analysis (FMEA). IEEE (2017).</Citation></Reference><Reference><Citation>Babiker, A. et al. Failure mode and effect analysis (FMEA) may enhance implementation of clinical practice guidelines: An experience from the Middle East. J. Eval. Clin. Pract. 24(1), 206–211. https://doi.org/10.1111/jep.12873 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jep.12873</ArticleId><ArticleId IdType="pubmed">29285849</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, G. et al. Point-prevalence surveys of hospital-acquired infections in a Chinese cancer hospital: From 2014 to 2018. J. Infect. Public Health 13(12), 1981–1987. https://doi.org/10.1016/j.jiph.2020.03.003 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.03.003</ArticleId><ArticleId IdType="pubmed">32280033</ArticleId></ArticleIdList></Reference><Reference><Citation>Daida, A. et al. Risk factors for hospital-acquired clostridium difficile infection among pediatric patients with cancer. J Pediatr Hematol Oncol 39(3), e167–e172. https://doi.org/10.1097/MPH.0000000000000742 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPH.0000000000000742</ArticleId><ArticleId IdType="pubmed">28002256</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkrief, A., Desilets, A., Papneja, N., et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study. Eur. J. Cancer,2020, 139(null):181–187. https://doi.org/10.1016/j.ejca.2020.08.017</Citation></Reference><Reference><Citation>Kirkire, M. S., Rane, S. B. &amp; Jadhav, J. R. Risk management in medical product development process using traditional FMEA and fuzzy linguistic approach: A case study. J. Ind. Eng. Int. 11(4), 595–611. https://doi.org/10.1007/s40092-015-0113-y (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40092-015-0113-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho, C. C. &amp; Liao, C. The use of failure mode and effects analysis to construct an effective disposal and prevention mechanism for infectious hospital waste. Waste Manag. 31(12), 2631–2637. https://doi.org/10.1016/j.wasman.2011.07.011 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wasman.2011.07.011</ArticleId><ArticleId IdType="pubmed">21807493</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochhar, A., Pronovost, P. J. &amp; Gourin, C. G. Hospital-acquired conditions in head and neck cancer surgery. Laryngoscope 123(7), 1660–1669. https://doi.org/10.1002/lary.23975 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.23975</ArticleId><ArticleId IdType="pubmed">23733563</ArticleId></ArticleIdList></Reference><Reference><Citation>Huoi, C. et al. Incidence of hospital-acquired pneumonia, bacteraemia and urinary tract infections in patients with haematological malignancies, 2004–2010: a surveillance-based study. PLoS One 8(3), e58121. https://doi.org/10.1371/journal.pone.0058121 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0058121</ArticleId><ArticleId IdType="pubmed">23472145</ArticleId><ArticleId IdType="pmc">3589363</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, D. et al. Risk factors for hospital-acquired bloodstream infections caused by extended-spectrum beta-lactamase Klebsiella pneumoniae among cancer patients. Ir J Med Sci 183(3), 463–469. https://doi.org/10.1007/s11845-013-1043-6 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-013-1043-6</ArticleId><ArticleId IdType="pubmed">24293294</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>